ARCT

SEC source: 0001193805-24-000426 · e619136_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 490,883

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 8,565 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 19, 2024, with sale prices ranging from $35.00 to $35.02 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-001627 · e619134_4-kummerfeld.xml · derivative · entry 1

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-12-15

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 15, 2024, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-23-001630 · e619137_4-sassine.xml · derivative · entry 1

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2033-12-15

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 15, 2024, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-23-001629 · e619136_4-chivukula.xml · derivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2033-12-15

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 15, 2024, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-23-001626 · e619133_4-payne.xml · derivative · entry 1

Payne Joseph E · CIK 0001727315 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-12-15

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 15, 2024, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-23-001628 · e619135_4-kurata.xml · derivative · entry 1

Kurata Lance · CIK 0001820961 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2033-12-15

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 15, 2024, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-23-001470 · e619041_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 499,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on November 1, 2023, with sale prices ranging from $18.39 to $19.27 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-001361 · e618979_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 504,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on October 2, 2023, with sale prices ranging from $25.29 to $26.32 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-001249 · e618918_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 509,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on September 1, 2023, with sale prices ranging from $30.70 to $31.75 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-001195 · e618886_4-sassine.xml · nonDerivative · entry 1

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 270,526

F1 · shares: Represents shares of common stock purchased by the Reporting Person pursuant to the Arcturus Therapeutics Holdings Inc. 2020 Employee Stock Purchase Plan (the "ESPP").

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 16, 2022.

SEC source: 0001193805-23-001073 · e618811_4-farrell.xml · derivative · entry 2

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Underlying: Common Stock · 3,131 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock.

F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001073 · e618811_4-farrell.xml · derivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,869

Underlying: Common Stock · 11,869 shares

Expires 2033-08-01

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001070 · e618808_4-barlow.xml · derivative · entry 2

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Underlying: Common Stock · 3,131 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock.

F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001070 · e618808_4-barlow.xml · derivative · entry 1

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,869

Underlying: Common Stock · 11,869 shares

Expires 2033-08-01

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001071 · e618809_4-holmes.xml · derivative · entry 2

HOLMES EDWARD W · CIK 0001197099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Underlying: Common Stock · 3,131 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock

F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001071 · e618809_4-holmes.xml · derivative · entry 1

HOLMES EDWARD W · CIK 0001197099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,869

Underlying: Common Stock · 11,869 shares

Expires 2033-08-01

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001069 · e618807_4-marquet.xml · derivative · entry 2

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Underlying: Common Stock · 3,131 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock

F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001069 · e618807_4-marquet.xml · derivative · entry 1

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,869

Underlying: Common Stock · 11,869 shares

Expires 2033-08-01

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001075 · e618822_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 514,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on August 1, 2023, with sale prices ranging from $34.44 to $35.70 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-001074 · e618812_4-markels.xml · derivative · entry 2

Markels John · CIK 0001803424 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Underlying: Common Stock · 3,131 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock.

F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001074 · e618812_4-markels.xml · derivative · entry 1

Markels John · CIK 0001803424 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,869

Underlying: Common Stock · 11,869 shares

Expires 2033-08-01

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001072 · e618810_4-jing.xml · derivative · entry 2

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Underlying: Common Stock · 3,131 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock.

F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001072 · e618810_4-jing.xml · derivative · entry 1

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,869

Underlying: Common Stock · 11,869 shares

Expires 2033-08-01

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-23-001002 · e618788_4-kummerfeld.xml · derivative · entry 7

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,938

Underlying: Common Stock · 1,031 shares

Expires 2030-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-23-001002 · e618788_4-kummerfeld.xml · derivative · entry 6

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,126

Underlying: Common Stock · 1,437 shares

Expires 2029-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-23-001002 · e618788_4-kummerfeld.xml · derivative · entry 5

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 4,500 shares

Expires 2028-07-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-23-001002 · e618788_4-kummerfeld.xml · nonDerivative · entry 4

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 950

F1 · shares: Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: These shares were sold in multiple transactions, each at a price of $35.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it on July 14, 2023.

SEC source: 0001193805-23-001002 · e618788_4-kummerfeld.xml · nonDerivative · entry 3

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,918

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193805-23-001002 · e618788_4-kummerfeld.xml · nonDerivative · entry 2

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,887

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193805-23-001002 · e618788_4-kummerfeld.xml · nonDerivative · entry 1

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193805-23-001003 · e618783_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 519,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 25,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on July 14, 2023, with sale prices ranging from $35.00 to $35.04 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-000955 · e618766_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 544,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on July 3, 2023, with sale prices ranging from $28.57 to $28.96 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-000824 · e618686_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 549,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on June 1, 2023, with sale prices ranging from $26.87 to $27.54 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-000719 · e618625_4-chivukula.xml · nonDerivative · entry 2

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 554,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: Reflects the weighted average price of 7,925 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on May 11, 2023, with sale prices ranging from $30.035 to $30.48 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-000719 · e618625_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 562,373

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 17,075 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on May 10, 2023, with sale prices ranging from $30.00 to $30.06 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-000656 · e618570_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 579,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions May 1, 2023 with sale prices ranging from $25.39 to $26.58 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-000578 · e618515_4-kummerfeld.xml · nonDerivative · entry 4

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 950

F1 · shares: Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $28.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on April 17, 2023.

SEC source: 0001193805-23-000578 · e618515_4-kummerfeld.xml · nonDerivative · entry 3

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,918

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193805-23-000578 · e618515_4-kummerfeld.xml · nonDerivative · entry 2

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193805-23-000578 · e618515_4-kummerfeld.xml · nonDerivative · entry 1

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,981

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193805-23-000578 · e618515_4-kummerfeld.xml · derivative · entry 7

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,563

Underlying: Common Stock · 1,437 shares

Expires 2029-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-23-000578 · e618515_4-kummerfeld.xml · derivative · entry 6

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,500

Underlying: Common Stock · 4,500 shares

Expires 2028-07-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-23-000578 · e618515_4-kummerfeld.xml · derivative · entry 5

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,969

Underlying: Common Stock · 1,031 shares

Expires 2030-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-23-000516 · e618445_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 584,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions April 3, 2023 with sale prices ranging from $23.56 to $26.12 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-23-000295 · e618338_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 589,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions March 6, 2023 with sale prices ranging from $15.66 to $16.09 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-22-001748 · e618133_4-marquet.xml · nonDerivative · entry 1

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Via Alma Life Sciences, LLC

Disclosed balance after: 24,942

SEC source: 0001193805-22-001716 · e618109_4-sassine.xml · derivative · entry 1

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-12-09

F1 · shares: Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-22-001714 · e618107_4-chivukula.xml · derivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-12-09

F1 · shares: Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-22-001715 · e618108_4-payne.xml · derivative · entry 1

Payne Joseph E · CIK 0001727315 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2032-12-09

F1 · shares: Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-22-001713 · e618106_4-kurata.xml · derivative · entry 1

Kurata Lance · CIK 0001820961 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-12-09

F1 · shares: Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.